In January, when Amgen launched the first biosimilar to compete with AbbVie’s Humira in the U.S., the company looked forward to six months of exclusivity in competing one-on-one against the immunology ...

Image above from a recent Humira ad. The Humira wars have begun, as the first branded biosimilar to break Abbvie’s 20-year exclusivity on the top-selling anti-inflammatory drug has launched, cutting ...

Amjevita’s revenue was down 63% in the second quarter (Q2) compared with the first quarter of 2023, when the biosimilar launched. The reference product, Humira, still had net revenues in the United ...

Amjevita (adalimumab-atto) is a brand-name drug prescribed for several inflammatory conditions in adults and some children. Amjevita comes as a solution for subcutaneous injection. The dosage can vary ...

Amgen announced today the launch of AMJEVITA (adalimumab-atto), a biosimilar to AbbVie’s HUMIRA (adalimumab), in the United States. AMJEVITA was the first HUMIRA biosimilar approved by the FDA and is ...

Amjevita (adalimumab-atto) is a prescription drug that’s used to manage certain inflammatory conditions, such as rheumatoid arthritis and plaque psoriasis. Amjevita comes as a liquid solution that’s ...